Perspective Therapeutics (CATX) vs Treace Medical Concepts (TMCI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Perspective Therapeutics (CATX) has outperformed Treace Medical Concepts (TMCI) over the past year, losing 29.1% versus a loss of 35.2%. Over five years, CATX leads with a -60.3% price change compared with -84.1% for TMCI. Perspective Therapeutics is the larger company by market cap ($279.1 million vs $251.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CATX | TMCI |
|---|---|---|
| Share price | $2.45 | $3.86 |
| Market cap | $279.10M | $251.03M |
| 1-day change | -0.61% | -0.77% |
| YTD return | -10.55% | +58.78% |
| 1-year return | -29.11% | -35.17% |
| 5-year return | -60.32% | -84.07% |
| EPS (TTM) | $-1.33 | $-0.92 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.16 | $7.08 |
| 52-week low | $1.96 | $1.17 |
| Distance from 52-week high | -60.31% | -45.48% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +402.66% | +42.49% |
| Average volume | 1.67M | 330.27K |
| Shares outstanding | 114.15M | 65.03M |
| Employees | 163 | 450 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Perspective Therapeutics
CATX stock →Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma; and PSV359, a targeted alpha therapy targeting fibroblast activation protein alpha.
Health Care · Biotechnology: Pharmaceutical Preparations · 163 employees
About Treace Medical Concepts
TMCI stock →Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty System, enables surgeons to correct all three dimensions of the bunion deformity, stabilize the first TMT joint, and allow return to weight-bearing in a walking boot; minimally invasive products for four bunion classes; Nanoplasty 3D Minimally Invasive Bunion Correction System delivers a reproducible 3D correction of the bunion deformity through a cosmetically appealing; and Percuplasty Percutaneous 3D Bunion Correction System that provides 3D correction of the bunion deformity through percutaneous incisions.
Health Care · Medical/Dental Instruments · 450 employees
CATX vs TMCI FAQ
Which is bigger, Perspective Therapeutics or Treace Medical Concepts?
Perspective Therapeutics (CATX) is larger, with a market capitalization of $279.10M compared with $251.03M for Treace Medical Concepts (TMCI).
Which stock has performed better over the past year, CATX or TMCI?
CATX returned -29.11% over the past 12 months, compared with -35.17% for TMCI (price return, excluding dividends). Past performance does not predict future results.
Are Perspective Therapeutics and Treace Medical Concepts in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Perspective Therapeutics and Medical/Dental Instruments for Treace Medical Concepts.